|
1.
|
|
|
2.
|
|
14 p, 2.2 MB |
Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer
/
Aguado, Cristina (Quirón Dexeus University Hospital) ;
Teixido, Cristina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Román, Ruth (Quirón Dexeus University Hospital) ;
Reyes, Roxana (Hospital Clínic i Provincial de Barcelona) ;
Giménez-Capitán, Ana (Quirón Dexeus University Hospital) ;
Marin, Elba (Hospital Clínic i Provincial de Barcelona) ;
Cabrera, Carlos (Grup Quirónsalud (Barcelona, Catalunya)) ;
Viñolas, Nuria (Hospital Clínic i Provincial de Barcelona) ;
Castillo, Sergi (Hospital General de Granollers) ;
Muñoz, Silvia (Hospital General de Granollers) ;
Arcocha, Ainara (Hospital Clínic i Provincial de Barcelona) ;
López-Vilaró, Laura (Institut d'Investigació Biomèdica Sant Pau) ;
Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ;
Aldeguer, Erika (Quirón Dexeus University Hospital) ;
Rodríguez, Sonia (Quirón Dexeus University Hospital) ;
Moya, Irene (Grup Quirónsalud (Barcelona, Catalunya)) ;
Viteri, Santiago (Quiron Salud Group) ;
Cardona, Andrés Felipe (Clínica del Country) ;
Palmero, Ramon (L'Hospitalet) ;
Sainz, Cristina (Centro de Investigación Biomédica en Red de Cáncer) ;
Mesa-Guzmán, Miguel (Universidad Pública de Navarra) ;
Lozano, Maria D. (Universidad Pública de Navarra) ;
Aguilar-Hernández, Andrés (Grup Quirónsalud (Barcelona, Catalunya)) ;
Martínez-Bueno, Alejandro (Grup Quirónsalud (Barcelona, Catalunya)) ;
González-Cao, María (Grup Quirónsalud (Barcelona, Catalunya)) ;
Gonzalvo, Elena (Hospital Clínic i Provincial de Barcelona) ;
Leenders, William P. J. (Radboud Institute for Molecular Life Sciences) ;
Rosell, Rafael (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Montuenga, Luis M. (Universidad Pública de Navarra) ;
Prat, Aleix (Hospital Clínic i Provincial de Barcelona) ;
Molina-Vila, Miguel Angel (Quirón Dexeus University Hospital) ;
Reguart, Noemi (Hospital Clínic i Provincial de Barcelona)
We studied MET alterations in 474 advanced non-small-cell lung cancer (NSCLC) patients by nCounter, an RNA-based technique. We identified 3% with MET Δex14 mRNA and 3. 5% with very-high MET mRNA expression, a surrogate of MET amplification. [...]
2020 -  10.1002/1878-0261.12861
Molecular Oncology, Vol. 15 (december 2020) , p. 350-363
|
|
|
3.
|
|
14 p, 572.1 KB |
Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer
/
Frigola Rissech, Joan (Vall d'Hebron Institut d'Oncologia) ;
Navarro, Alejandro (Vall d'Hebron Institut d'Oncologia) ;
Carbonell, Caterina (Vall d'Hebron Institut d'Oncologia) ;
Callejo, Anna (Vall d'Hebron Institut d'Oncologia) ;
Iranzo, Patricia (Vall d'Hebron Institut d'Oncologia) ;
Cedrés, Susana (Vall d'Hebron Institut d'Oncologia) ;
Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia) ;
Pardo, Nuria (Vall d'Hebron Institut d'Oncologia) ;
Saoudi-Gonzalez, Nadia (Vall d'Hebron Institut d'Oncologia) ;
Martinez, D. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Jiménez, José (Vall d'Hebron Institut d'Oncologia) ;
Sansano, Irene (Hospital Universitari Vall d'Hebron) ;
Mancuso, Francesco M. (Vall d'Hebron Institut d'Oncologia) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Montuenga, L.M. (Instituto de Investigación Sanitaria de Navarra) ;
Sánchez-Cespedes, Montse (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Prat, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Felip, Enriqueta (Vall d'Hebron Institut d'Oncologia) ;
Amat, Ramón (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Immunotherapy has transformed advanced non-small cell lung cancer (NSCLC) treatment strategies and has led to unprecedented long-lasting responses in some patients. However, the molecular determinants driving these long-term responses remain elusive. [...]
2020 - 10.1002/1878-0261.12891
Molecular Oncology, 2020
|
|
|
4.
|
|
|
5.
|
|
14 p, 892.1 KB |
Discovery of novel DNA methylation biomarkers for non-invasive sporadic breast cancer detection in the Latino population
/
Cappetta, M. (Departamento de Genética. Facultad de Medicina. Universidad de la República) ;
Fernandez, L. (Departamento de Genética. Facultad de Medicina. Universidad de la República) ;
Brignoni, L. (Departamento de Genética. Facultad de Medicina. Universidad de la República) ;
Artagaveytia, N. (Departamento Básico de Medicina. Facultad de Medicina. Universidad de la República) ;
Bonilla, C. (Population Health Sciences. Bristol Medical School. University of Bristol) ;
López, Miguel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bertoni, B. (Departamento de Genética. Facultad de Medicina. Universidad de la República) ;
Berdasco, Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
Human diversity is one of the main pitfalls in the development of robust worldwide biomarkers in oncology. Epigenetic variability across human populations is associated with different genetic backgrounds, as well as variable lifestyles and environmental exposures, each of which should be investigated. [...]
2021 - 10.1002/1878-0261.12842
Molecular Oncology, Vol. 15 Núm. 2 (february 2021) , p. 473-486
|
|
|
6.
|
|
16 p, 1.9 MB |
Epigenetic-smoking interaction reveals histologically heterogeneous effects of TRIM27 DNA methylation on overall survival among early-stage NSCLC patients
/
Ji, X. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Lin, L. (Department of Environmental Health. Harvard T.H. Chan School of Public Health) ;
Shen, S. (China International Cooperation Center for Environment and Human Health. Nanjing Medical University) ;
Dong, X. (Department of Epidemiology and Biostatistics. School of Public Health. Southeast University) ;
Chen, C. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Li, Y. (Department of Biostatistics. University of Michigan) ;
Zhu, Y. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Huang, H. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Chen, J. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Chen, X. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Wei, Liangmin (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
He, J. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Duan, W. (Department of Bioinformatics. School of Biomedical Engineering and Informatics. Nanjing Medical University) ;
Su, L. (Department of Environmental Health. Harvard T.H. Chan School of Public Health) ;
Jiang, Y. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Fan, J. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Guan, J. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
You, D. (Department of Environmental Health. Harvard T.H. Chan School of Public Health) ;
Shafer, A. (Harvard Medical School) ;
Bjaanæs, M.M. (Department of Cancer Genetics. Institute for Cancer Research. Oslo University Hospital) ;
Karlsson, A. (Division of Oncology and Pathology. Department of Clinical Sciences Lund and CREATE Health Strategic Center for Translational Cancer Research. Lund University) ;
Planck, M. (Division of Oncology and Pathology. Department of Clinical Sciences Lund and CREATE Health Strategic Center for Translational Cancer Research. Lund University) ;
Staaf, J. (Division of Oncology and Pathology. Department of Clinical Sciences Lund and CREATE Health Strategic Center for Translational Cancer Research. Lund University) ;
Helland, Å. (Institute of Clinical Medicine. University of Oslo) ;
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Wei, Y. (China International Cooperation Center for Environment and Human Health. Nanjing Medical University) ;
Zhang, R. (China International Cooperation Center for Environment and Human Health. Nanjing Medical University) ;
Chen, F. (Jiangsu Key Lab of Cancer Biomarkers. Prevention and Treatment. Cancer Center. Collaborative Innovation Center for Cancer Personalized Medicine. Nanjing Medical University) ;
Christiani, D.C. (Harvard Medical School) ;
Universitat Autònoma de Barcelona
Tripartite motif containing 27 (TRIM27) is highly expressed in lung cancer, including non-small-cell lung cancer (NSCLC). Here, we profiled DNA methylation of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) tumours from 613 early-stage NSCLC patients and evaluated associations between CpG methylation of TRIM27 and overall survival. [...]
2020 - 10.1002/1878-0261.12785
Molecular Oncology, Vol. 14 Núm. 11 (january 2020) , p. 2759-2774
|
|
|
7.
|
|
15 p, 1.9 MB |
Silencing of adaptor protein 32 reduces / receptors expression and impairs gastrointestinal stromal tumors growth
/
Serrano-Candelas, Eva (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Ainsua-Enrich, Erola (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Navinés-Ferrer, Arnau (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Rodrigues, Paulo (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
García-Valverde, Alfonso (Vall d'Hebron Institut d'Oncologia) ;
Bazzocco, Sarah (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
García-Valverde, Alfonso (Vall d'Hebron Institut d'Oncologia) ;
Macaya, Irati (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
García-Valverde, Alfonso (Vall d'Hebron Institut d'Oncologia) ;
Arribas, Joaquín V (Universitat Autònoma de Barcelona) ;
Serrano, César (Hospital Universitari Vall d'Hebron) ;
Sayós, Joan (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Arango, Diego (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martin, Margarita (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Gastrointestinal stromal tumors (s) represent about 80% of the mesenchymal neoplasms of the gastrointestinal tract. Most s contain oncogenic (85%) or (5%) receptors. The kinase inhibitor imatinib mesylate is the preferential treatment for these tumors; however, the development of drug resistance has highlighted the need for novel therapeutic strategies. [...]
2018 - 10.1002/1878-0261.12332
Molecular Oncology, Vol. 12 (june 2018) , p. 1383-1397
|
|
|
8.
|
|
4 p, 147.6 KB |
Towards a Cancer Mission in Horizon Europe
/
Berns, Anton (European Academy of Cancer Sciences) ;
Ringborg, Ulrik (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
Eggermont, Alexander (Gustave Roussy Cancer Campus Grand Paris) ;
Baumann, Michael (German Cancer Consortium) ;
Calvo, Fabien (Gustave Roussy Cancer Campus Grand Paris) ;
Eggert, Angelika (Charite-Universitatsmedizin) ;
Espina, Carolina (International Agency for Research on Cancer) ;
Hanahan, Douglas (Federal Institute of Technology in Lausanne) ;
Lacombe, Denis (EORTC Headquarters) ;
De Lorenzo, Francesco (European Cancer Patient Coalition) ;
Oberst, Simon (Organisation of European Cancer Institutes) ;
Philip, Thierry (Institut Curie) ;
Schüz, Joachim (International Agency for Research on Cancer) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Celis, Julio E. (Danish Cancer Society Research Centre) ;
Universitat Autònoma de Barcelona
2019 - 10.1002/1878-0261.12585
Molecular Oncology, Vol. 13 (october 2019) , p. 2301-2304
|
|
|
9.
|
|
|
10.
|
|
9 p, 351.5 KB |
Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS -mutant metastatic colorectal cancer
/
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Chianese, Chiara (Vall d'Hebron Institut d'Oncologia) ;
Sanz-García, Enrique (Vall d'Hebron Institut d'Oncologia) ;
Martinelli, Erica (Università della Campania 'L. Vanvitelli') ;
Noguerido, Alba (Vall d'Hebron Institut d'Oncologia) ;
Mancuso, Francesco M (Vall d'Hebron Institut d'Oncologia) ;
Caratù, Ginevra (Vall d'Hebron Institut d'Oncologia) ;
Matito, Judit (Vall d'Hebron Institut d'Oncologia) ;
Grasselli, Julieta (Vall d'Hebron Institut d'Oncologia) ;
Cardone, Claudia (Università della Campania 'L. Vanvitelli') ;
Esposito Abate, Riziero (Istituto Nazionale Tumori 'Fondazione Giovanni Pascale' IRCCS) ;
Martini, Giulia ;
Santos Vivas, Cristina (Universitat de Barcelona) ;
Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ;
Argilés, Guillem (Vall d'Hebron Institut d'Oncologia) ;
Garcia, Ariadna (Vall d'Hebron Institut d'Oncologia) ;
Mulet, Nuria (Universitat de Barcelona) ;
Maiello, Evaristo (IRCCS Casa Sollievo della Sofferenza) ;
Normanno, Nicola (Istituto Nazionale Tumori 'Fondazione Giovanni Pascale' IRCCS) ;
Jones, Frederick (Sysmex Inostics) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Ciardello, Fortunato (Università della Campania 'L. Vanvitelli') ;
Salazar, Ramon (Universitat de Barcelona) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Despite major advances in the treatment of metastatic colorectal cancer (mCRC), the survival rate remains very poor. This study aims at exploring the prognostic value of RAS -mutant allele fraction (MAF) in plasma in mCRC. [...]
2019 - 10.1002/1878-0261.12547
Molecular Oncology, Vol. 13 (july 2019) , p. 1827-1835
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
